Top 5 Stock Gainers for Monday: Pfizer, Trillium, NextGen


The Nasdaq closed at a record Monday after U.S. regulators issued full approval for the coronavirus vaccine made by Pfizer  (PFE) – Get Report and partner BioNTech.  (BNTX) – Get Report

Here are some of the top gainers for Monday:

1. Pfizer | Increase 2.5%

Pfizer shares moved up after the U.S. Food and Drug Administration issued full approval for the coronavirus vaccine made by the New York health-care giant and partner BioNTech. The German company's shares jumped 9.6%.

The agency late last year granted emergency-use authorization for the vaccine.

TheStreet RecommendsPRESS RELEASESFuel Additives Market Revenue Worth $7,990.6 Million By 2030 Says P&S Intelligence12 minutes agoPRESS RELEASESHow To Manage Stress While Moving House, According To Jake Removals And Storage12 minutes agoPRESS RELEASESEpson Enhances Productivity For Small Offices And Workgroups With Wide-format WorkForce Pro WF-7310 Printer27 minutes ago2. Trillium | Increase 189%

Shares of Trillium Therapeutics  (TRIL) – Get Report as much as tripled on Monday after Pfizer said it would buy the company, a deal that values the immuno-oncology specialist at around $2.3 billion. Pfizer invested $25 million in Trillium last year.

3. NextGen Acquisition | Increase 1.9%

NextGen Acquisition Corp. II  (NGCA) – Get Report shares rose after Richard Branson's Virgin Orbit said it would go public by merging with the special purpose acquisition company. The deal values Virgin Orbit at about $3.2 billion. Boeing  (BA) – Get Report has committed to investing in the satellite-launching startup.

4. Exxon Mobil | Increase 4.1%

Shares of Exxon Mobil  (XOM) – Get Report climbed after the energy giant said it planned to resume talks with the Papua New Guinea government on the P'nyang natural gas project nearly two years after their negotiations halted. The talks, tied to a $13 billion expansion of the country's liquefied natural gas exports, had fallen apart with the government saying Exxon was unwilling to negotiate on the country’s terms, Reuters reported.

5. Vivos Therapeutics | Increase 54%

Vivos Therapeutics  (VVOS) – Get Report shares soared after the medical-technology provider garnered FDA clearance for a device to treat sleep apnea. More than 1 billion people globally and 54 million Americans suffer from sleep apnea, and 80% are undiagnosed, Vivos said.

Boeing is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells the stock? Learn more now.

Leave a Reply

Your email address will not be published.